Cargando…

Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment

In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test...

Descripción completa

Detalles Bibliográficos
Autores principales: De Felice, Francesca, Musio, Daniela, Tombolini, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151395/
https://www.ncbi.nlm.nih.gov/pubmed/34068797
http://dx.doi.org/10.3390/jpm11050393
_version_ 1783698372770660352
author De Felice, Francesca
Musio, Daniela
Tombolini, Vincenzo
author_facet De Felice, Francesca
Musio, Daniela
Tombolini, Vincenzo
author_sort De Felice, Francesca
collection PubMed
description In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research.
format Online
Article
Text
id pubmed-8151395
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81513952021-05-27 Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment De Felice, Francesca Musio, Daniela Tombolini, Vincenzo J Pers Med Review In head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research. MDPI 2021-05-10 /pmc/articles/PMC8151395/ /pubmed/34068797 http://dx.doi.org/10.3390/jpm11050393 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
De Felice, Francesca
Musio, Daniela
Tombolini, Vincenzo
Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title_full Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title_fullStr Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title_full_unstemmed Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title_short Immune Check-Point Inhibitors and Standard Chemoradiotherapy in Definitive Head and Neck Cancer Treatment
title_sort immune check-point inhibitors and standard chemoradiotherapy in definitive head and neck cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151395/
https://www.ncbi.nlm.nih.gov/pubmed/34068797
http://dx.doi.org/10.3390/jpm11050393
work_keys_str_mv AT defelicefrancesca immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment
AT musiodaniela immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment
AT tombolinivincenzo immunecheckpointinhibitorsandstandardchemoradiotherapyindefinitiveheadandneckcancertreatment